Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för rigosertib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

10 träffar

Bibliografisk träff 2019-07-16

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Balaian E, Weidner H, Wobus M, Baschant U, Jacobi A, Mies A, Bornhäuser M, Guck J, Hofbauer LC, Rauner M, Rauner M, Platzbecker U.

Ann Hematol · journal article · DOI 10.1007/s00277-019-03756-1

Bibliografisk träff 2019-07-12

Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice.

Qin H, Jiang Y, Zhang J, Deng C, Zhong Z.

Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.molpharmaceut.9b00691

Bibliografisk träff 2019-03-08

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia.

Baker SJ, Cosenza SC, Ramana Reddy MV, Premkumar Reddy E.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.26735

Bibliografisk träff 2017-11-11

A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.

Navada SC, Fruchtman SM, Odchimar-Reissig R, Demakos EP, Petrone ME, Zbyszewski PS, Holland JF, Silverman LR.

Leuk Res · clinical trial, phase ii; clinical trial, phase i; journal article · DOI 10.1016/j.leukres.2017.11.006

Bibliografisk träff 2017-10-01

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.

Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, Kampmann M, Akhmanova A, Steinmetz MO, Tanenbaum ME, Weissman JS.

Mol Cell · research-article; journal article · DOI 10.1016/j.molcel.2017.09.012

Bibliografisk träff 2017-10-01

[Anti-Tumor Effect of Rigosertib on HEL and K562 Cells and Its Related Mechanism].

Xu F, Chang CK, Li X, He Q, Wu LY, Zhang Z.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · journal article · DOI 10.7534/j.issn.1009-2137.2017.05.014

Bibliografisk träff 2016-11-01

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.

Prasad A, Khudaynazar N, Tantravahi RV, Gillum AM, Hoffman BS.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.12692

Bibliografisk träff 2016-04-13

ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.

Dai YH, Hung LY, Chen RY, Lai CH, Chang KC.

Transl Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.trsl.2016.04.001

Bibliografisk träff 2005-10-01

Polo-like kinase (Plk) 1 as a target for prostate cancer management.

Reagan-Shaw S, Ahmad N.

IUBMB Life · review; journal article · DOI 10.1080/15216540500305910

Bibliografisk träff 2005-03-01

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP.

Cancer Cell · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ccr.2005.02.009